Loading organization details...
The organization you're looking for doesn't exist or has been removed.
Back to Organizations| Sub-Organization | Type | Status | Funding |
|---|
| Announced Date | Transaction Name | Investors | Money Raised | Lead Investors | Funding Type |
|---|
| Investor Name | Lead Investor | Funding Round | Partners |
|---|
| Organization Name | Lead Investor | Funding Round |
|---|
| Announced Date | Organization Name | Diversity Spotlight | Funding Round | Money Raised |
|---|
| Acquiree Name | Announced Date | Price | Transaction Name |
|---|
Matched by industry, location, employee size, and funding stage.
Preclinical Assets focus on small-molecule inhibitors targeting the Sec61 translocon to enable targeted protein degradation.
Canonical: https://fsome.com/organization/kezar-life-sciences-preclinical-assets-17198786 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.
Sign in to view detailed metrics, contact information, and financial data. Upgrade your account to access the full dataset — including funding history, team contacts, and real-time company insights.